Senior Clinical Research Fellow
Parminder K Judge is a Senior Clinical Research Fellow based in the Renal Studies Group at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU).
Parminder studied medicine at the University of Birmingham. After completing her core medical training in Leicester, she undertook specialty training in nephrology in the Oxford rotation. In 2013, she took time ‘out-of-programme for research’ to work on clinical trials. She worked primarily on the UK HARP-III trial which compared the effects of sacubitril/valsartan (a novel angiotensin-receptor neprilysin inhibitor) with irbesartan (an angiotensin receptor blocker) on in 400 people with chronic kidney disease. The trial formed the basis of her PhD thesis.
She also undertook the adjudication of clinical outcomes for the 3C trial and provided clinical support for the REVEAL and ASCEND trials. She participated in epidemiological analyses of the SHARP trial assessing the effects of blood pressure on cardiovascular outcomes. Parminder used HES data to establish and quantify previously undocumented hepatorenal complications in polycystic kidney disease and, to determine the risk of many established complications of the disease.
After completing her nephrology specialty training in 2020, Parminder returned to CTSU to work on clinical trials in nephrology and cardiovascular disease, including the EMPA-KIDNEY trial. She now aims to develop her knowledge and experience of clinical trials, testing new treatments aimed at managing and reducing the progression of chronic kidney disease.
She continues to practice nephrology within the Oxford Kidney Unit and has an active interest in teaching clinical trainees, undergraduate and postgraduate students.
Chronic kidney disease, heart failure and neprilysin inhibition.
Haynes R. et al, (2019), Nephrol Dial Transplant
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R. et al, (2018), Circulation, 138, 1505 - 1514
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
3C Study Collaborative Group None., (2018), Am J Transplant, 18, 1424 - 1434
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group None. et al, (2017), N Engl J Med, 377, 1217 - 1227
Biliary Tract and Liver Complications in Polycystic Kidney Disease.
Judge PK. et al, (2017), J Am Soc Nephrol, 28, 2738 - 2748